메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Choi Ui Yoon (Department of Pediatrics Eunpyeong St. Mary's Hospital College of Medicine The Catholic University) Kim Ki Hwan (Department of Pediatrics Incheon St. Mary's Hospital College of Medicine The Catholic University of) Lee Jin (Department of Pediatrics Hanil General Hospital Seoul Korea.) Eun Byung Wook (Department of Pediatrics Nowon Eulji University Hospital Eulji University School of Medicine Seoul) Kim Hwang Min (Department of Pediatrics Wonju Severance Christian Hospital Yonsei University Wonju College of Medi) Lee Kyung-Yil (Department of Pediatrics Daejeon St. Mary's Hospital College of Medicine The Catholic University of) Kim Dong Ho (Department of Pediatrics Korea Cancer Center Hospital Seoul Korea.) Ma Sang Hyuk (Department of Pediatrics Changwon Fatima Hospital Changwon Korea.) Lee Jina (Department of Pediatrics Asan Medical Center University of Ulsan College of Medicine Seoul Korea.) Kim Jong-Hyun (Department of Pediatrics St. Vincent's Hospital College of Medicine The Catholic University of Kore)
저널정보
대한의학회 Journal of Korean Medical Science Journal of Korean Medical Science Vol.36 No.49
발행연도
2021.12
수록면
1 - 11 (11page)
DOI
10.3346/jkms.2021.36.e313

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Although the combination tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) is recommended at adolescence in developed countries, the tetanus and diphtheria toxoid vaccine (Td), which is less costly, is recommended instead in some parts of the world. A new Td, BR-TD-1001, was developed by a Korean manufacturer for distribution to endemic regions and for use in the initial step of novel Tdap development. Methods: This phase 3, randomized, double-blind, multi-center trial, conducted in Korea, aimed to evaluate the immunogenicity and safety of BR-TD-1001. Healthy children aged 10 to 12 years were randomized 1:1 to receive either BR-TD-1001 or the control Td (Td-pur, GlaxoSmithKline). Antibodies were measured using enzyme-linked immunosorbent assay. Results: A total of 218 subjects (BR-TD-1001, n = 108; control, n = 110) were enrolled and included in the safety analysis. Vaccine-mediated antibody responses were similar in both groups. We confirmed the non-inferiority of BR-TD-1001 against the control, Td; 100% of both groups achieved seroprotection against diphtheria and tetanus. Furthermore, there was no significant difference between groups in the proportion of participants who demonstrated boost responses against diphtheria and tetanus toxoids. The incidence of solicited local and systemic adverse events (AEs), unsolicited AEs, and serious AEs did not differ significantly between groups. Conclusion: The BR-TD-1001 satisfied the immunological non-inferiority criterion against diphtheria and tetanus, with a clinically acceptable safety profile.

목차

등록된 정보가 없습니다.

참고문헌 (29)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0